REVIEW
|
doi:10.20944/preprints201909.0140.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
hepatocellular carcinoma; immune checkpoint inhibitors; HCC; pembrolizumab; nivolumab; immune microenvironment; targeted therapies
Online: 14 September 2019 (18:37:29 CEST)